AstraZeneca is looking to scale up supply ahead of a possible US fast-track approval in which its partner is a cell therapy firm.
The British drugmaker is making steadfast progress in developing the coronavirus vaccine hopeful AZD1222.
More recently, the British company scored big when its drug, Imfinzi, was approved for use in Europe to treat an aggressive form of lung cancer.
AstraZeneca’s drugs for cancer, diabetes, and heart disease rather make up its main treatment portfolio.
The company's shares gained as much as 1.5 percent to trade at 84.6 pounds by 8:07am GMT, outperforming the benchmark FTSE-100 index, after Oxford Biomedica announced the expanded agreement and on news of the EU approval for Imfinzi.
Cambridge-based AstraZeneca's vaccine is among the leading candidates in the global race for a successful vaccine and it has entered late-stage trials in the United States, the company said on Monday, as it targets 3 billion doses of the vaccine, globally.
Oxford Biomedica said in a statement that AstraZeneca would give it 15 million pounds ($20 million) upfront to reserve manufacturing capacity at Oxford Biomedica's plant and that it could get an additional £35 million under a new 18-month deal.